[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"detail-sidebar-cat-0-en-105":3,"doc-seo-351861-105":59,"doc-detail-351861-en":130},{"code":4,"msg":5,"data":6},0,"success",[7,13,18,23,28,33,38,43,48,51,55],{"id":8,"doc_module":4,"doc_module_name":9,"category_name":10,"show_sort_weight":11,"slug":12},1,"Document","Story & Novel",90,"story-novel",{"id":14,"doc_module":4,"doc_module_name":9,"category_name":15,"show_sort_weight":16,"slug":17},2,"Literature",80,"literature",{"id":19,"doc_module":4,"doc_module_name":9,"category_name":20,"show_sort_weight":21,"slug":22},4,"Exam",70,"exam",{"id":24,"doc_module":4,"doc_module_name":9,"category_name":25,"show_sort_weight":26,"slug":27},5,"Comic",60,"comic",{"id":29,"doc_module":4,"doc_module_name":9,"category_name":30,"show_sort_weight":31,"slug":32},6,"Technology",50,"technology",{"id":34,"doc_module":4,"doc_module_name":9,"category_name":35,"show_sort_weight":36,"slug":37},7,"Healthcare",40,"healthcare",{"id":39,"doc_module":4,"doc_module_name":9,"category_name":40,"show_sort_weight":41,"slug":42},8,"Research & Report",30,"research-report",{"id":44,"doc_module":4,"doc_module_name":9,"category_name":45,"show_sort_weight":46,"slug":47},9,"Religion & Spirituality",20,"religion-spirituality",{"id":46,"doc_module":4,"doc_module_name":9,"category_name":49,"show_sort_weight":46,"slug":50},"World Cup","world-cup",{"id":52,"doc_module":4,"doc_module_name":9,"category_name":53,"show_sort_weight":52,"slug":54},10,"Lifestyle","lifestyle",{"id":56,"doc_module":4,"doc_module_name":9,"category_name":57,"show_sort_weight":24,"slug":58},19,"General","general",{"code":4,"msg":60,"data":61},"ok",{"site_id":62,"language":63,"slug":64,"title":65,"keywords":66,"description":67,"schema_data":68,"social_meta":123,"head_meta":125,"extra_data":127,"updated_unix":129},105,"en","translational-perspectives-on-cell-free-mitochondrial-dna-as-a-biomarker-in-gynecological-cancers-current-limitations-and-future-research-directions","Translational Perspectives on Cell-Free Mitochondrial DNA as a Biomarker in Gynecological Cancers - Current Limitations and Future Research Directions","","Liquid biopsy offers a non-invasive route for tumor-derived biomarker detection, and circulating cell-free DNA (cfDNA)—including nuclear and mitochondrial fractions—has been widely studied for diagnosis, monitoring, and prognosis. Mitochondrial DNA (mtDNA) is often present at higher concentrations, making circulating cell-free mitochondrial DNA (cfmtDNA) potentially detectable. cfmtDNA is linked to pro-inflammatory signaling and cellular damage processes such as apoptosis, necrosis, and NETosis. This review summarizes cfmtDNA alterations in ovarian and endometrial cancers, critically evaluates evidence for biomarker utility, and outlines current limitations and future research directions.",{"@graph":69,"@context":122},[70,84,105],{"@type":71,"itemListElement":72},"BreadcrumbList",[73,77,79,82],{"item":74,"name":75,"@type":76,"position":8},"https://docshare.wps.com","Home","ListItem",{"item":78,"name":9,"@type":76,"position":14},"https://docshare.wps.com/document/",{"item":80,"name":40,"@type":76,"position":81},"https://docshare.wps.com/document/research-report/",3,{"item":83,"name":65,"@type":76,"position":19},"https://docshare.wps.com/document/translational-perspectives-on-cell-free-mitochondrial-dna-as-a-biomarker-in-gynecological-cancers-current-limitations-and-future-research-directions/351861/",{"url":83,"name":65,"@type":85,"image":86,"author":91,"headline":65,"publisher":94,"fileFormat":97,"inLanguage":63,"description":67,"dateModified":98,"datePublished":99,"encodingFormat":97,"isAccessibleForFree":100,"interactionStatistic":101},"DigitalDocument",{"url":87,"@type":88,"width":89,"height":90},"https://docshare.wps.com/thumbnails/translational-perspectives-on-cell-free-mitochondrial-dna-as-a-biomarker-in-gynecological-cancers-current-limitations-and-future-research-directions/351861.png","ImageObject",300,407,{"name":92,"@type":93},"4398046744996","Person",{"url":74,"name":95,"@type":96},"DocShare","Organization","application/pdf","2026-11-16","2026-09-22",true,{"@type":102,"interactionType":103,"userInteractionCount":52},"InteractionCounter",{"@type":104},"ViewAction",{"@type":106,"mainEntity":107},"FAQPage",[108,114,118],{"name":109,"@type":110,"acceptedAnswer":111},"Why is cell-free mitochondrial DNA (cfmtDNA) considered detectable in body fluids?","Question",{"text":112,"@type":113},"Mitochondrial DNA typically has a higher copy number per cell than nuclear DNA, so mitochondrial DNA fractions are often present at higher concentrations and may be easier to detect in circulation.","Answer",{"name":115,"@type":110,"acceptedAnswer":116},"What biological processes link cfmtDNA to tumor activity?",{"text":117,"@type":113},"cfmtDNA is associated with pro-inflammatory signaling and cellular damage responses, including apoptosis, necrosis, and neutrophil extracellular trap formation (NETosis).",{"name":119,"@type":110,"acceptedAnswer":120},"Which gynecological cancers are reviewed for cfmtDNA biomarker potential?",{"text":121,"@type":113},"The review focuses on the most prevalent gynecological malignancies, particularly ovarian and endometrial cancers.","https://schema.org",{"og:url":83,"og:type":124,"og:title":65,"og:site_name":95,"og:description":67},"article",{"robots":126,"canonical":83},"index,follow",{"doc_id":128,"site_id":62},351861,1790187201,{"code":4,"msg":5,"data":131},{"doc_id":128,"user_id":132,"nickname":92,"user_avatar":66,"doc_module":4,"category_id":39,"category_name":40,"doc_title":65,"doc_description":67,"doc_content":133,"file_id":134,"file_url":135,"file_type":136,"file_size":137,"view_count":52,"is_deleted":4,"is_public":8,"is_downloadable":8,"audit_status":8,"page_count":138,"language":139,"language_code":63,"site_id":62,"html_lang":63,"table_of_contents":140,"faqs":141,"seo_title":142,"seo_description":67,"update_tm":143,"read_time":36,"preview_page_count":19,"preview_urls":144},4398046744996,"Review  \nTranslational Perspectives on Cell-Free Mitochondrial DNA as a Biomarker in Gynecological Cancers: Current Limitations and Future Research Directions  \nClara Musicco 1, Anna Signorile 2, Domenico De Rasmo 1, Vera Loizzi 2,3, Gennaro Cormio 3,4 and Antonella Cormio 5, *  \nAcademic Editor: Charles Lawrie  \nReceived: 12 March 2026  \nRevised: 8 May 2026  \nAccepted: 18 May 2026  \nPublished: 25 May 2026  \nCopyright: © 2026 by the authors. Licensee MDPI, Basel, Switzerland. This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license.  \n1 Institute of Biomembranes, Bioenergetics and Molecular Biotechnologies (IBIOM), National Research Council  \nof Italy (CNR), 70126 Bari, Italy; [clara.musicco@cnr.it](clara.musicco@cnr.it) (C.M.); [domenico.derasmo@cnr.it](domenico.derasmo@cnr.it) (D.D.R.)  \n2 Department of Translational Biomedicine and Neuroscience, University of Bari ‘Aldo Moro’, 70124 Bari, Italy; [anna.signorile@uniba.it](anna.signorile@uniba.it) (A.S.); [vera.loizzi@uniba.it](vera.loizzi@uniba.it) (V.L.)  \n3 S.C. Ginecologia Oncologia Clinicizzata, IRCCS Istituto Tumori Giovanni Paolo II, 70124 Bari, Italy; [gennaro.cormio@uniba.it](gennaro.cormio@uniba.it)  \n4 Department of Interdisciplinary Medicine, University of Bari ‘Aldo Moro’, 70124 Bari, Italy  \n5 Department of Precision and Regenerative Medicine and Ionian Area, University of Bari ‘Aldo Moro’, 70124 Bari, Italy  \n* Correspondence: [antonella.cormio@uniba.it](antonella.cormio@uniba.it)  \nAbstract  \nIn recent years, liquid biopsy has emerged as a promising non-invasive strategy for the identification of tumor-derived biomarkers. Among circulating analytes, cell-free DNA (cfDNA), including both nuclear and mitochondrial fractions, has been extensively investigated in a variety of biological fluids for its potential applications in cancer diagnosis, disease monitoring, and prognostic stratification. Owing to its higher copy number per cell compared with nuclear DNA, mitochondrial DNA (mtDNA) is typically present at higher concentrations in body fluids and is therefore potentially detectable. Circulating cell-free mitochondrial DNA (cfmtDNA) is closely associated with pro-inflammatory signaling pathways and cellular damage responses, including apoptosis, necrosis, and neutrophil extracellular trap formation (NETosis) . This review provides a comprehensive overview of the reported alterations of cfmtDNA in the most prevalent gynecological malignancies, namely ovarian and endometrial cancers, which are characterized by a chronic inflammatory microenvironment. We further critically assess the current evidence supporting cfmtDNA as a potential non-invasive biomarker in these malignancies, highlighting current limitations and future research directions.  \nKeywords: liquid biopsy; cancer biomarkers; cell-free DNA; cell-free mitochondrial DNA; ovarian cancer; endometrial cancer  \n1. Introduction  \nTissue biopsy remains the standard approach for cancer diagnosis; however, it is inherently invasive. In recent years, the analysis of specific biomarkers in liquid biopsies, including serum, plasma, saliva, ascitic fluid, and urine, has emerged as a promising and non-invasive strategy for early cancer detection, accurate prognosis, and evaluation of therapeutic response [1,2] .  \nLiquid biopsy analytes include cell-free DNA (cfDNA), protein antigens, circulating tumor cells (CTCs), cell-free RNA (cfRNA), and extracellular vesicles (EVs) [2] . Based on  \ntheir cellular origin, cfDNA can be classified as cell-free nuclear DNA (cfnDNA) or cellfree mitochondrial DNA (cfmtDNA). Cell-free RNA comprises messenger RNA (mRNA), microRNA (miRNA), circular RNA (circRNA) and long non-coding RNA (lncRNA) [2–5] . Figure 1 summarizes the main classes of analytes investigated in liquid biopsy.  \nFigure 1. Analytes analyzed in liquid biopsy: protein antigens; CTC, cancer tumor cell; EVs, extracellular vesicles; cfRNA, cell-f","cbCaifdu3RYsMv4C","https://ap.wps.com/l/cbCaifdu3RYsMv4C","pdf",1182257,16,"English","# Introduction\n## Liquid biopsy and cfDNA categories\n# Cell-Free DNA\n## Sources, fragment characteristics, and release mechanisms\n# Cell-Free Mitochondrial DNA (cfmtDNA) as a biomarker\n## Association with inflammation and tumor microenvironment\n# cfmtDNA in gynecological malignancies\n## Ovarian and endometrial cancers\n# Evidence assessment and future directions\n## Limitations and knowledge gaps","[{\"question\":\"Why is cell-free mitochondrial DNA (cfmtDNA) considered detectable in body fluids?\",\"answer\":\"Mitochondrial DNA typically has a higher copy number per cell than nuclear DNA, so mitochondrial DNA fractions are often present at higher concentrations and may be easier to detect in circulation.\"},{\"question\":\"What biological processes link cfmtDNA to tumor activity?\",\"answer\":\"cfmtDNA is associated with pro-inflammatory signaling and cellular damage responses, including apoptosis, necrosis, and neutrophil extracellular trap formation (NETosis).\"},{\"question\":\"Which gynecological cancers are reviewed for cfmtDNA biomarker potential?\",\"answer\":\"The review focuses on the most prevalent gynecological malignancies, particularly ovarian and endometrial cancers.\"}]","Translational Perspectives on Cell-Free Mitochondrial DNA as a Biomarker in Gynecological Cancers - Current Limitations and Future Research Directions | PDF",1790096351,[145,149,153,157],{"page_no":8,"url":146,"width":147,"height":148},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/bef64bc190661b5e5bde450f6ee80bec.webp",983,1390,{"page_no":14,"url":150,"width":151,"height":152},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/46e73f2df874bbad67bc639f07164d0c.webp",982,1388,{"page_no":81,"url":154,"width":155,"height":156},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0f6269e7b75505a5f0af8997966d3c30.webp",981,1387,{"page_no":19,"url":158,"width":159,"height":160},"https://res-academy.cache.wpscdn.com/upload/kdocshare/2026-11-16/0e9dbec0d9eef0c1afb93ce4158bdbdc.webp",980,1385]